542 related articles for article (PubMed ID: 16429148)
21. Applications of Hemagglutinating Virus of Japan in therapeutic delivery systems.
Kaneda Y
Expert Opin Drug Deliv; 2008 Feb; 5(2):221-33. PubMed ID: 18248320
[TBL] [Abstract][Full Text] [Related]
22. Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.
Wright JF; Qu G; Tang C; Sommer JM
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):174-8. PubMed ID: 12669452
[TBL] [Abstract][Full Text] [Related]
23. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.
Huttner NA; Girod A; Perabo L; Edbauer D; Kleinschmidt JA; Büning H; Hallek M
Gene Ther; 2003 Dec; 10(26):2139-47. PubMed ID: 14625569
[TBL] [Abstract][Full Text] [Related]
24. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.
Wang Z; Zhu T; Qiao C; Zhou L; Wang B; Zhang J; Chen C; Li J; Xiao X
Nat Biotechnol; 2005 Mar; 23(3):321-8. PubMed ID: 15735640
[TBL] [Abstract][Full Text] [Related]
25. Hybrid of baculovirus and galactosylated PEI for efficient gene carrier.
Kim YK; Choi JY; Jiang HL; Arote R; Jere D; Cho MH; Je YH; Cho CS
Virology; 2009 Apr; 387(1):89-97. PubMed ID: 19272627
[TBL] [Abstract][Full Text] [Related]
26. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders.
Terzi D; Zachariou V
Biotechnol J; 2008 Dec; 3(12):1555-63. PubMed ID: 19072910
[TBL] [Abstract][Full Text] [Related]
27. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy.
Michelfelder S; Lee MK; deLima-Hahn E; Wilmes T; Kaul F; Müller O; Kleinschmidt JA; Trepel M
Exp Hematol; 2007 Dec; 35(12):1766-76. PubMed ID: 17920758
[TBL] [Abstract][Full Text] [Related]
28. Targeting the heart with gene therapy-optimized gene delivery methods.
Müller OJ; Katus HA; Bekeredjian R
Cardiovasc Res; 2007 Feb; 73(3):453-62. PubMed ID: 17097076
[TBL] [Abstract][Full Text] [Related]
29. Clinical gene therapy using recombinant adeno-associated virus vectors.
Mueller C; Flotte TR
Gene Ther; 2008 Jun; 15(11):858-63. PubMed ID: 18418415
[TBL] [Abstract][Full Text] [Related]
30. Designing gene delivery vectors for cardiovascular gene therapy.
Baker AH
Prog Biophys Mol Biol; 2004; 84(2-3):279-99. PubMed ID: 14769440
[TBL] [Abstract][Full Text] [Related]
31. Use of herpes simplex virus type 1-based amplicon vector for delivery of small interfering RNA.
Sabbioni S; Callegari E; Manservigi M; Argnani R; Corallini A; Negrini M; Manservigi R
Gene Ther; 2007 Mar; 14(5):459-64. PubMed ID: 17051250
[TBL] [Abstract][Full Text] [Related]
32. Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors.
Farson D; Harding TC; Tao L; Liu J; Powell S; Vimal V; Yendluri S; Koprivnikar K; Ho K; Twitty C; Husak P; Lin A; Snyder RO; Donahue BA
J Gene Med; 2004 Dec; 6(12):1369-81. PubMed ID: 15538729
[TBL] [Abstract][Full Text] [Related]
33. Controlled dissemination of AAV vectors in the primate brain.
Varenika V; Kells AP; Valles F; Hadaczek P; Forsayeth J; Bankiewicz KS
Prog Brain Res; 2009; 175():163-72. PubMed ID: 19660655
[TBL] [Abstract][Full Text] [Related]
34. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
35. Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios.
Aucoin MG; Perrier M; Kamen AA
Biotechnol Bioeng; 2006 Dec; 95(6):1081-92. PubMed ID: 16952153
[TBL] [Abstract][Full Text] [Related]
36. Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening.
Sorscher EJ; Harris J; Alexander M; Rottgers A; Hardy K; Ponnazhagan S; Collawn JF; McClintock J; Amsler CD; Webster A; Maddry J; Baker BJ; Hong JS
Gene Ther; 2006 May; 13(9):781-8. PubMed ID: 16307002
[TBL] [Abstract][Full Text] [Related]
37. Considerations and challenges for the achievement of targeted gene delivery.
Curiel DT
Gene Ther; 1999 Sep; 6(9):1497-8. PubMed ID: 10490758
[No Abstract] [Full Text] [Related]
38. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
[TBL] [Abstract][Full Text] [Related]
39. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
40. Viral vectors for gene delivery in tissue engineering.
Zhang X; Godbey WT
Adv Drug Deliv Rev; 2006 Jul; 58(4):515-34. PubMed ID: 16762441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
